Advertisement

Topics

Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress

02:00 EDT 15 Sep 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Pfizer Inc. (NYSE:PFE) today announced results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, compared to placebo, in patients with mode...

Other Sources for this Article

Pfizer Inc.
Media:
Neha Wadhwa
212-733-2835
Neha.Wadhwa@pfizer.com
or
Dervila Keane
+353 86 2110834
Dervila.M.Keane@pfizer.com
or
Investors:
Bryan Dunn
212-733-8917
Bryan.Dunn@pfizer.com

NEXT ARTICLE

More From BioPortfolio on "Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...